Molly Harper - 20 Nov 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director
Signature
/s/ Molly Harper
Issuer symbol
CPRX
Transactions as of
20 Nov 2025
Net transactions value
$0
Form type
4
Filing time
24 Nov 2025, 20:08:27 UTC
Previous filing
19 Feb 2025
Next filing
10 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Harper Molly Director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Molly Harper 24 Nov 2025 0001871470

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +947 +14% 7,693 21 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Award $0 +18,115 +14% $0.000000 145,389 20 Nov 2025 Common Stock 18,115 $22.77 Direct F2
transaction CPRX Restricted Stock Units Award $0 +5,468 +3.8% $0.000000 150,857 20 Nov 2025 Common Stock 5,468 Direct F2, F3
transaction CPRX Restricted Stock Units Options Exercise $0 -947 -0.63% $0.000000 149,910 21 Nov 2025 Common Stock 947 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
F3 Shares of common stock will be delivered to the Reporting Person upon vesting.
F4 Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
F5 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.